tbuckley/cabot-search huggingface dataset:
Potential Toxic Side Effects of Folic Acid
Authors: Faiz Kakar, Ph.D., Maureen M. Henderson, M.D.
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Potential Toxic Side Effects of Folic Acid Get access Faiz Kakar, Ph.D., Faiz Kakar, Ph.D. Cancer Prevention Research Unit Fred Hutchinson Cancer Research Center 1124 Columbia Street Seattle, Washington 98104 Search for other works by this author on: Oxford Academic PubMed Google Scholar Maureen M. Henderson, M.D. Maureen M. Henderson, M.D. Cancer Prevention Research Unit Fred Hutchinson Cancer Research Center 1124 Columbia Street Seattle, Washington 98104 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 74, Issue 1, January 1985, Page 263, https://doi.org/10.1093/jnci/74.1.263 Published: 01 January 1985
PTU-271 Hidden morbidity following colorectal resection: postoperative evaluation
Authors: GC Thorpe, J Hernon
Journal: Gut (2015)

<h3>Introduction</h3> The implementation and evaluation of Enhanced Recovery after Surgery programmes over the past 15 years has ensured the accurate reporting of inpatient morbidity post colorectal resection. However, there is a paucity of audit or research examining post-operative morbidity in the early discharge period. <h3>Method</h3> 142 consecutive patients undergoing elective (n = 98) or emergency (n = 44) colorectal resection over a three-month period were invited to attend a nurse-led outpatient clinic at 30 days post-discharge. Audit data were collected at two time-points, discharge from hospital and at clinic. Audit templates were developed using the Postoperative Morbidity Survey,<sup>1</sup>Clavien-Dindo classification criteria<sup>2</sup>and modified to include additional colorectal surgery-specific outcomes. Results were recorded and analysed using SPSS. <h3>Results</h3> Unanticipated findings relating to post-discharge morbidity identified through the audit included: 35% (n = 32) of infection-free inpatients developed surgical site infections following discharge. 34% (n = 47) of all patients had significant urinary symptoms when seen in clinic. Dietary implications at 30 days post-discharge included an appetite of half or less than usual intake in 27% of patients (n = 37) and moderate to major changes in dietary intake compared to their pre-operative diet in 30% (n = 42). 27% (n = 38) of patients had an ileostomy; of those without an ileostomy, 20% (n = 21) had four or more daily bowel movements, with 22% (n = 23) describing their stool consistency as watery, loose or unsettled. 45% (n = 46) of those without an ileostomy reported one or more problematic bowel symptom related to their surgical experience at 30 days post-discharge. <h3>Conclusion</h3> These audit findings suggest that individuals undergoing colorectal resection experience significant levels of post-discharge morbidity, extending the burden on them and the services required to support them for longer than may have been previously anticipated. Nurse-led follow-up using auditable documentation templates facilitates the recognition and reporting of complications following discharge and provides valuable support for patients. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Grocott MPW, <i>et al</i>. The Postoperative Morbidity Survey was validated and used to describe morbidity after pelvic surgery. J Clin Epidemiol 2007;60:919–928 Dindo D, <i>et al</i>. Classification of Surgical Complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213
Studies of Various Tests for Malignant Neoplastic Diseases. IV. The Effect of Zinc Ion upon the Serum Alkaline Phosphatase Activity
Authors: Ellerbrook, Lester D., Lippincott, Stuart W., Chipps, H. Davis
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Studies of Various Tests for Malignant Neoplastic Diseases. IV. The Effect of Zinc Ion upon the Serum Alkaline Phosphatase Activity Get access Lester D. Ellerbrook, Lester D. Ellerbrook Search for other works by this author on: Oxford Academic PubMed Google Scholar Stuart W. Lippincott, Stuart W. Lippincott Search for other works by this author on: Oxford Academic PubMed Google Scholar H. Davis Chipps H. Davis Chipps Clinical Trials Unit, Cancer Control Branch, National Cancer Institute, Bethesda, Md., and Department of Pathology, School of Medicine, University of Washington, Seattle, Wash. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 4, February 1951, Pages 739–755, https://doi.org/10.1093/jnci/11.4.739 Published: 01 February 1951 Article history Received: 26 September 1950 Published: 01 February 1951
SP0047 The Minority Patient's Journey; Delay in Seeking Medical Help, Beliefs About Medicines and Consequences for Adherence to Treatment
Authors: K. Kumar
Journal: Annals of the Rheumatic Diseases (2015)

Rheumatoid arthritis (RA) is a common chronic condition that impacts on patients9 health related quality of life. Furthermore, RA has been associated with reduced life expectancy as it increases the risk of death from various causes including cardiovascular disease, and infections. Effective medications exist to control RA but only if used within a window period In the UK, we have found prolonged delays in patients9 seeking medical help amongst the South Asian RA patients which could have consequences on disease outcome and treatment. Treatments such as disease modifying anti-rheumatic drugs (DMARDs) have side effects and patients do not always adhere to them. It has been shown that culturally related health beliefs can influence medication adherence in chronic disease and this may affect long term outcomes. In the UK, South Asian patients with RA have been shown to have different beliefs about medicines from White patients. To fully engage patients from these minority ethnic backgrounds in RA management, it is important to know how health beliefs interact with perceptions about the disease and medicines used to treat it. This session will uncover some of the issues in patients9 journey. <h3>Disclosure of Interest</h3> None declared
Blood Plasma Sulfhydryl Levels During Growth and Regression of the Murphy Lymphosarcoma of the Rat&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Shacter, Bernard, Entenman, Cecil, Shimkin, Michael B.
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Blood Plasma Sulfhydryl Levels During Growth and Regression of the Murphy Lymphosarcoma of the Rat Get access Bernard Shacter, Bernard Shacter Search for other works by this author on: Oxford Academic PubMed Google Scholar Cecil Entenman, Cecil Entenman Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin Michael B. Shimkin Biological and Medical Sciences Division, U. S. Naval Radiological Defense Laboratory, and the Laboratory of Experimental Oncology, National Cancer Institute3 and the Division of Medicine, University of California School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 3, December 1952, Pages 647–656, https://doi.org/10.1093/jnci/13.3.647 Published: 01 December 1952 Article history Received: 07 July 1952 Published: 01 December 1952
Salvage treatment of ovarian cancer.
Authors: F M Muggia
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.11.3420 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9363877 Salvage treatment of ovarian cancer. F M MuggiaxF M MuggiaSearch for articles by this author https://doi.org/10.1200/JCO.1997.15.11.3420 PDF "Salvage treatment of ovarian cancer.." Journal of Clinical Oncology, 15(11), pp. 3420–3421© 1997 by American Society of Clinical Oncology
Treatment of Cryptococcal Meningitis
Authors: B S Zingman
Journal: New England Journal of Medicine (1997)

To the Editor: Cumming et al. (July 3 issue) 1 concluded that "the use of inhaled corticosteroids is associated with the development of posterior subcapsular and nuclear cataracts" without considering possible confounders, including a history of atopic dermatitis 2-4 and the use of topical corticosteroids on the face and eyelids. 5Both factors were probably present in at least some of the study subjects.It is likely that both were more common in the subjects who were using inhaled corticosteroids than in those who were not, since a major indication for the use of inhaled corticosteroids is allergic asthma, an atopic condition often found in persons with atopic dermatitis.
SP0116 Lost in Translation – How to Understand What Clinicians Talk About
Authors: D. Scheel-Toellner
Journal: Annals of the Rheumatic Diseases (2015)

For successful translational research it is of key importance that communication between researchers mainly based in the clinic and those working in a laboratory setting functions effectively. This presentation will highlight some characteristic problems the speaker has encountered at the interface of clinical and non-clinical staff and will offer a few suggestions to avoid misunderstandings and misconceptions <h3>Disclosure of Interest</h3> None declared
Prevention in mental health: a controlled study
Authors: P R Polak, D Egan, R Vandenbergh, W V Williams
Journal: American Journal of Psychiatry (1975)

The authors conducted a controlled study in which families who had experienced the sudden death of a family member were given crisis intervention services and compared at follow-up with two untreated control groups. Results did not support the hypothesis that such services decrease the risk of psychiatric illness, disturbed family functioning, or increased social cost to the families. The authors suggest that environmental and social systems factors and individual variables are powerful predictors of outcome in bereavement.
Counting costs of care.
Authors: J C McVie
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.10.1529 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2845010 Counting costs of care. J C McViexJ C McVieSearch for articles by this author https://doi.org/10.1200/JCO.1988.6.10.1529 First Page PDF © 1988 by American Society of Clinical Oncology
The Biological Effects and the Chemical Composition of Podophyllin. A Review
Authors: Margaret G. Kelly, Jonathan L. Hartwell
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article The Biological Effects and the Chemical Composition of Podophyllin. A Review Get access Margaret G. Kelly, Margaret G. Kelly Laboratory of Chemical Pharmacology, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Jonathan L. Hartwell Jonathan L. Hartwell Laboratory of Chemical Pharmacology, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 4, February 1954, Pages 967–1010, https://doi.org/10.1093/jnci/14.4.967 Published: 01 February 1954 Article history Received: 20 April 1953 Published: 01 February 1954
AB0316 Patterns of Disease Remission Among Patients with Rheumatoid Arthritis Treated with Biologic theRapies in Japan
Authors: S. Narayanan, Y. Lu, R. Hutchings, A. Baskett
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Disease remission is a key target while managing patients with Rheumatoid Arthritis (RA). <h3>Objectives</h3> To assess the patterns of disease remission among RA patients recently treated with biologic therapies in Japan. <h3>Methods</h3> A multi-center medical chart-review study of RA patients was conducted among physicians (rheumatologists) in hospitals/private practices to collect de-identified data on patients who were currently on a biologic or recently discontinued a biologic within past 3-months. Physicians were screened for practice-duration and patient-volume and recruited from a large panel to be geographically representative of Japan. Patient charts of ∼10 successive patients visiting each center/practice during study period were selected. Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status (incl. assessment of "disease remission", per physician clinical judgment (both objective &amp; subjective)). <h3>Results</h3> In 4Q2011, physicians abstracted 435 eligible RA patient charts; 79%, 17%and 3% were on 1st line, 2nd line and 3rd line biologic respectively. Overall, 49% of patients were in remission; the mean duration of remission status was 16.7 months. Remission-rate differed by biologic lines: 1st-line:53%, 2nd-line:41%, 3rd-line:21%. Among those with lab measures, results differed between those in remission vs. those who were not: mean ESR (mm/h): 18.1 vs. 30.6, mean CRP (mg/dl): 0.5 vs. 1.2, mean MMP3 (ng/ml): 84.7-vs-136.7, Rheumatoid Factor (% positive): 87%&gt;vs-91% and Anti-CCP (% positive): 91%&gt;vs-94%. Among those with available data, recent (mean) disease severity scores differed between those in remission vs. those who were not: Tender Joint Count: 0.8-vs-2.7, Swollen Joint Count: 0.8-vs-2.6, 100mm VAS score: 12.8-vs-32.2, HAQ: 0.1-vs-0.2 and DAS28: 1.8-vs-3.7. <h3>Conclusions</h3> Approximately half of the patients were not in remission in this cohort of RA patients in Japan who were treated with a biologic; they experienced disproportionate level of disease burden. As the line of treatment increased, proportion of individuals achieving remission decreased. These observed patterns warrant further scrutiny to determine the best practices and improve remission rates, thereby alleviating patient burden. <h3>Disclosure of Interest</h3> S. Narayanan Employee of: Ipsos, Y. Lu Employee of: Ipsos, R. Hutchings Employee of: Ipsos, A. Baskett Employee of: Ipsos
AB0178 IL-12 Inhibits the Production of IL-10 in Patients with Sjogren Syndrome
Authors: G. Yao, W. Chen, X. Tang, X. Feng, L. Sun
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Interleukin (IL)-12, IL-23, IL-27, and IL-35 constitute a unique family of structurally-related, heterodimeric cytokines, which regulate immune response and inflammatory reactions. IL-12 family has been reported to be involved in the pathogenesis of autoimmune diseases <sup>[1-2]</sup>. However, the role of IL-12 family on Sjogren syndrome (SS) and related mechanisms remained to be elucidated. <h3>Objectives</h3> Since the IL-12 family has been shown to regulate the generation of T regulatory 1 (Tr1) cells and Tr1 cells have been indicated a functional role in disease progress of SS through their secretion of the immunosuppressive cytokine IL-10<sup>[3-4]</sup>. The aim of the present study was to identify the specific members of IL-12 family involved in the pathogenesis of SS and to explore the relationship of IL-12 family cytokines with IL-10. <h3>Methods</h3> 20 SS patients, 20 RA patients, 20 SLE patients and 20 healthy volunteers were recruited in the present study. Expressions of IL-12, IL-23, IL-27, and IL-35 in peripheral blood mononuclear cells (PBMCs) from patients with SS, RA, SLE and healthy controls were determined by quantitative PCR. Plasma levels of IL-12, IL-27 and IL-10 were detected by Enzyme-linked Immunosorbent Assay. <h3>Results</h3> IL-12 and IL-27 mRNA significantly increased in PBMCs from patients with SS than healthy controls. Increased plasma levels of IL-12 and IL-27 have been confirmed in SS patients. Plasma IL-12 and IL-27 correlated with clinic indexes, such as anti-SSA, anti-SSB and ANA antibodies. IL-12 levels showed a negative correlation with plasma IL-10. However, no significant correlation was found between plasma IL-27 and IL-10 (Fig1). <h3>Conclusions</h3> These findings suggested that IL-12 might have a pivotal role in the development and progression of SS through suppression of differentiation of IL-10-producing Tr1 cells. Therapeutic targeting IL-12 and Tr1 cells might be useful in the modulating of SS. <h3>References</h3> Gee K, Guzzo C, Che Mat NF, et al. The IL-12 family of cytokined in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets, 2009, 8(1):40-52. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol, 2012, 13(8): 722-8 Tsoumakidou M, Tousa S, Semitekolou M, et al. Tolerogenic signaling by pulmonary CD1c<sup>+</sup> dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand. J Allergy Clin Immunol, 2014, 134(4): 944-54. Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory cells (Tr1) in autoimmunity. Semin Immunol, 2011, 23(3):202-8. <h3>Disclosure of Interest</h3> None declared
Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing
Authors: M Alvarez do Barrio, R González Díez, J M Hernández Sánchez, S Oyonarte Gómez
Journal: Eurosurveillance (2005)

Estimates of the risk of bloodborne viral infections are essential for monitoring the safety of the blood supply and the impact of new screening tests. Incidence rates of seroconversion and the residual risk for HBV, HIV and HCV were calculated among Spanish repeat donors between 1997 and 1999 at 22 blood donation centres, and at 7 centres between 2000 and 2002. The residual risk per million donations was estimated to be 18.67 for HBV, 2.49 for HIV and 10.96 for HCV (between 1997 and 1999). For the 2000-2002 period, the residual risk per million donations was estimated to be 9.78 for HBV, 2.48 for HIV and 3.94 for HCV. Between 1999 and 2003, about 3.4 million donations were tested by NAT, mainly in pools of 44 donations, in 12 of the 22 Spanish blood donation centres participating in the study. Eight anti-HCV negative and HCV-RNA positive donations were found, which represent an approximate yield of 1/420,000, versus a projected yield of 1/240,000 obtained from 1995-1997 data. The residual risks of transfusion-transmitted viral infections in Spain were low, and with the implementation of NAT these risks are even lower.
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Authors: Richard J. Jones, Tawin Iempridee, Xiaobin Wang, Hans C. Lee, Janet E. Mertz, Shannon C. Kenney, Heather C. Lin, Veerabhadran Baladandayuthapani, Christopher W. Dawson, Jatin J. Shah, Donna M. Weber, Robert Z. Orlowski
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Lenalidomide, thalidomide, and pomalidomide (LTP) are immunomodulatory agents approved for use in multiple myeloma, but in some settings, especially with alkylating agents, an increase in Hodgkin lymphoma and other secondary primary malignancies (SPM) has been noted. Some of these malignancies have been linked to Epstein–Barr virus (EBV), raising the possibility that immunomodulatory drugs disrupt latent EBV infection. Experimental Design: We studied the ability of LTP to reactivate latently infected EBV-positive cell lines in vitro and in vivo, and evaluated the EBV viral load in archived serum samples from patients who received a lenalidomide, thalidomide, and dexamethasone (LTD) combination. Results: Treatment of EBV-infected B-cell lines with LTP at physiologically relevant concentrations induced the immediate early gene BZLF1, the early gene BMRF1, and the late proteins VCA and BCFR1. This occurred in the potency order pomalidomide &amp;gt; lenalidomide &amp;gt; thalidomide, and the nucleoside analogue ganciclovir enhanced the cytotoxic effects of lenalidomide and pomalidomide in Burkitt lymphoma cells in vitro and in vivo. EBV reactivation was related to PI3K stimulation and Ikaros suppression, and blocked by the PI3Kδ inhibitor idelalisib. Combinations of lenalidomide with dexamethasone or rituximab increased EBV reactivation compared with lenalidomide alone and, importantly, lenalidomide with melphalan produced even greater reactivation. Conclusions: We conclude LTP may reactivate EBV-positive resting memory B cells thereby enhancing EBV lytic cycle and host immune suppression. Clin Cancer Res; 22(19); 4901–12. ©2016 AACR.
Combustible and Smokeless Tobacco Use Among High School Athletes — United States, 2001–2013
Authors: Israel T. Agaku, Tushar Singh, Sherry Everett Jones, Brian A. King, Ahmed Jamal, Linda Neff, Ralph S. Caraballo
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Athletes are not a typical at-risk group for smoking combustible tobacco products, because they are generally health conscious and desire to remain fit and optimize athletic performance (1). In contrast, smokeless tobacco use historically has been associated with certain sports, such as baseball (2). Athletes might be more likely to use certain tobacco products, such as smokeless tobacco, if they perceive them to be harmless (3); however, smokeless tobacco use is not safe and is associated with increased risk for pancreatic, esophageal, and oral cancers (4). Tobacco use among youth athletes is of particular concern, because most adult tobacco users first try tobacco before age 18 years (5). To examine prevalence and trends in current (≥1 day during the past 30 days) use of combustible tobacco (cigarettes, cigars) and smokeless tobacco (chewing tobacco, snuff, or dip [moist snuff]) products among athlete and nonathlete high school students, CDC analyzed data from the 2001–2013 National Youth Risk Behavior Surveys. Current use of any tobacco (combustible or smokeless tobacco) significantly declined from 33.9% in 2001 to 22.4% in 2013; however, current smokeless tobacco use significantly increased from 10.0% to 11.1% among athletes, and did not change (5.9%) among nonathletes. Furthermore, in 2013, compared with nonathletes, athletes had significantly higher odds of being current smokeless tobacco users (adjusted odds ratio [AOR] = 1.77, p<0.05), but significantly lower odds of being current combustible tobacco users (AOR = 0.80, p<0.05). These findings suggest that opportunities exist for development of stronger tobacco control and prevention measures targeting youth athletes regarding the health risks associated with all forms of tobacco use.
Aortico-Left Ventricular Tunnel
Authors: Z Sutlić, Z Kokos, V Fabecić-Sabadi, B Biocina, N Protrka, J Sokolić
Journal: JAMA (1963)

The boy was first admitted to the Department of Pediatric Cardiology at the age of 4 1/2 because of cardiac murmur diagnosed on the third day of life. A diastolic murmur of a grade 4/6, left ventricular hypertrophy as well as left aortal and ventricular dilatation were discovered. The findings showed a tendency of increase with time, but the patient had no symptoms. X-ray in the long axis view revealed a defect within the upper part of the interventricular septum immediately below the aorta, and dilated right coronary sinus. An invasive diagnostic method was undertaken, as well. The operative procedure was done with a total cardio-pulmonary bypass and hypothermia (29 degrees C). A tunnel from the anterior aortal wall through the outflow tract of the right ventricle to the left side of the heart was established intraoperatively. The defect was solved by a "sandwich" technique (two patch technique). Postoperative period was uneventful. A Doppler echocardiogram demonstrated the normal hemodynamic status of the patient without the left-to-right or right-to-left shunt and aortal insufficiency.